Skip to content

Rational-emotional Behavioral Therapy (REBT) in Patients With Osteoarthritis and Concomitant Diseases Before Arthroplasty

Rational-emotional Behavioral Therapy in Patients With Osteoarthritis and Concomitant Diseases Before Knee or Hip Arthroplasty

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05971797
Acronym
REBT
Enrollment
95
Registered
2023-08-02
Start date
2020-01-01
Completion date
2021-12-31
Last updated
2023-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Anxiety, Pain

Keywords

Depression, Anxiety, Rational Emotive Behavior Therapy, Arthroplasty, Osteoarthritis, Comorbidities

Brief summary

The objective of this study was evaluation of the effectiveness of REBT on the emotional state of orthopedic patients with comorbidities before and after arthroplasty.

Detailed description

The studies assessed depression or anxiety in orthopedic patients by using Spielberger State-Trait Anxiety Inventory (STAI) and Hospital Anxiety and Depression Scale (HADS) before and after athroplasty. The comorbid background studied. The orthopedic patients with comorbidities were divided into several groups: arterial hypertension, chronic pyelonephritis , varicose veins, cardiovascular disease and atherosclerosis, diabetes mellitus, infection diseases, gastrointestinal diseases, obesity, neurological disorder, cerebrovascular accident, iron deficiency anemia, chronic bronchitis, hyperthyroidism, cardiac arrhythmia, other diseases. Patients with high levels of anxiety and depression underwent Rational Emotive Behavior Therapy before surgery. Patients without comorbidities and patients with comorbidities but without exposure considered as a control.

Interventions

BEHAVIORALREBT

During REBT in patients with osteoarthritis and concomitant diseases with diagnosed depression or anxiety before arthroplasty the patients learn how to manage their irrational or unhealthy emotions, thoughts, and behaviors.

Sponsors

Chuvash State University named after I.N. Ulyanov
CollaboratorUNKNOWN
Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Randomized clinical trial in patients with depression or anxiety identified at prior psychological counseling prior to joint replacement surgery with or without comorbidities

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients enrolled for the primary knee or hip arthroplasty (M15.0, M16, M17) before operation.

Exclusion criteria

* Other types of psychiatric pathology * Reluctance to undergo psychological correction * Failure to pass pre-test * Ongoing follow-up with a psychologist or psychiatrist

Design outcomes

Primary

MeasureTime frameDescription
STAI2 days after surgeryEach subscale uses a 4-point Likert scale with a range from 1 (not at all for S- or almost never for T-Anxiety) to 4 (very much so for S- and almost always for T-Anxiety). Reverse scoring is used for anxiety-absent items (e.g., I feel calm or I am happy), and therefore, a higher score indicates more severe anxiety with a potential range from 20 to 80 for each subscale. According to the developer scores of 20-39, 40-59, and 60-80 indicate low, moderate, and high anxiety, respectively. Normative values are available in the manual.
HADS2 days after surgeryThe HADS is a self-report rating scale of 14 items on a 4-point Likert scale (range 0-3). with a range from 0 (not at all) to 3 (most of the time). Reverse scoring is used for items with positive wording (e.g., I still enjoy the things I used to enjoy). The total score is the sum of the 14 items, and for each subscale the score is the sum of the respective seven items (ranging from 0-21). A score of 8-10 should be classified as a mild disorder, 11-15 as a moderate disorder, and 16 or more as a severe disorder.

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026